Actively Recruiting
Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
Led by Sunnybrook Health Sciences Centre · Updated on 2023-12-14
150
Participants Needed
3
Research Sites
791 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This work explores the possibility of using ultrasound imaging and spectroscopy as a way of monitoring cell death, hence, tumour response to treatment. The hypothesis here is that it can be used as a way of monitoring early response to cancer treatment and predicting which patients continue on in their therapy to have a complete pathological response as a primary endpoint and tumour size decrease as a secondary endpoint. If this work is successful it could be used in the future early on in a cancer patient's treatment to predict whether or not a course of chemotherapy or radiotherapy is going to be successful. For example, in patients in which the analysis indicates a poor response the chemotherapy regimen could be changed to a more efficacious one or for those receiving radiotherapy predicted to have a poor response a radiosensitizing agent could be used to improve outcome.
CONDITIONS
Official Title
Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed locally advanced breast carcinoma not previously treated with first-line therapy and planned for neoadjuvant chemotherapy or combined chemo-radiotherapy
- Measurable disease by ultrasound or MRI performed within 28 days prior to treatment
- Eastern Co-operative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy of at least 6 months
- Ability and willingness to provide written informed consent prior to study procedures
You will not qualify if you...
- History of allergic reactions to compounds with similar chemical or biological composition
- Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- Psychiatric illness or social situations limiting compliance with study requirements
- Any unstable condition that could jeopardize patient safety or compliance with the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
MD Anderson
Houston, Texas, United States, 77030
Completed
2
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
3
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Completed
Research Team
G
Gregory J Czarnota, PhD, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here